Table 5.
Log-lank Test and Univariate and Multivariate Analysis for Overall Survival.
| Factor | Category | Median OS, m (95% CI) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| p value | HR (95% CI) | p value | ||||
| Histology | Adeno | NA (48.1-NA) | 1 | |||
| Squamous | 23.8 (14.6-NA) | <0.01 | 2.32 (1.00-5.37) | <0.05 | ||
| Age (years) | <75 | NA (39.9-NA) | 1 | |||
| ≥75 | 23.9 (6.47-NA) | <0.05 | 1.02 (0.97-1.07) | 0.40 | ||
| Gender | Female | NA (22.4-NA) | ||||
| Male | 48.1 (39.9-NA) | 0.86 | ||||
| ECOG-PS | 0, 1 | 48.1 (39.9-NA) | 1 | |||
| 2, 3 | 5.02 (1.22-NA) | <0.05 | 1.62 (0.69-3.82) | 0.27 | ||
| Alb (mg/dL) | ≥3.3 | NA (39.9-NA) | 1 | |||
| <3.3 | 23.9 (6.41-NA) | <0.05 | 1.15 (0.42-3.06) | 0.80 | ||
| CRP (mg/dL) | ≤1.2 | NA (33.1-NA) | ||||
| >1.2 | 42.9 (16.8-NA) | 0.15 | ||||
| GPS | 0, 1 | NA (39.9-NA) | ||||
| 2 | 23.9 (7.06-NA) | 0.06 | ||||
| Hb (mg/dL) | ≥12.4 | NA (NA-NA) | 1 | |||
| <12.4 | 23.9 (16.8-48.1) | <0.01 | 1.22 (0.93-1.61) | 0.15 | ||
| PD-L1 TPS (%) | >10 | NA (23.9-NA) | 1 | |||
| ≤10 | 23.0 (14.6-48.1) | <0.05 | 1.01 (1.00-1.02) | 0.07 | ||
| T factor | T1-T3 | NA (42.9-NA) | ||||
| T4 | 39.9 (16.8-NA) | 0.09 | ||||
| N factor | N3 | NA (NA-NA) | ||||
| N0-2 | 48.1 (23.8-NA) | 0.15 | ||||
Age, ECOG-PS, Alb, CRP, Hb, PD-L1, T factor and N factor were divided into two groups where the most difference occurred with reference to ROC curve. m: months, HR: hazard ratio, CI: confidence interval, Adeno: adenocarcinoma, Squamous: squamous cell carcinoma, ECOG: Eastern Cooperative Oncology Group, PS: performance status, Alb: albumin, CRP: C-reactive protein, GPS: Glasgow Prognostic Score, Hb: hemoglobin, PD-L1: programmed cell death ligand 1, TPS: tumor proportion score